Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. (scientific article published on 24 September 2013)

Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released

Q34584213

Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis

Q35153802

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

Q35960196

Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes

Q36313419

Low-molecular-weight heparins and angiogenesis

Q36414904

Platelet secretion is kinetically heterogeneous in an agonist-responsive manner

Q36509648

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

Q36597453

Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype

Q36650343

From Trousseau to angiogenesis: the link between the haemostatic system and cancer.

Q36688214

Tumoral angiogenesis and breast cancer

Q37416806

Heparin as an inhibitor of cancer progression.

Q37784315

The platelet contribution to cancer progression

Q37805788

The role of blood platelets in tumor angiogenesis

Q37822079

Contribution of platelets to tumour metastasis.

Q37831798

Inhibition of tumor metastasis by heparanase inhibiting species of heparin.

Q38313060

Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography

Q39379451

Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis

Q40576775

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

Q42647384

Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.

Q42799749

The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets

Q43197783

The effect of LMWH (Nadroparin) on tumor progression

Q43276023

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

Q44550490

Cell biology. Beyond clotting: the powers of platelets

Q44781954

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Q44895898

Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid

Q45130652

Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin.

Q45997448

A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation

Q46320328

The effect of low molecular weight heparin on survival in patients with advanced malignancy

Q47392658

Thrombin induces the release of angiopoietin-1 from platelets.

Q55034619

Impact of pretreatment thrombocytosis on survival in primary breast cancer

Q59616859

Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin

Q62607067

Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine

Q69602939

Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines

Q70854025

Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties

Q71303804

Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets

Q71660878

Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival

Q73423057

Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer

Q73671443

Nonremodeling properties of matrix metalloproteinases: the platelet connection

Q74211042

Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans

Q79248994

Prognostic significance of thrombocytosis in node-negative colon cancer

Q81573580

Serum vascular endothelial growth factors a, C and d in human breast tumors

Q84701414

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

anticoagulation

Q63279445

P304

page(s)

101-112

P577

publication date

2013-09-24

P1433

published in

Blood

Q885070

P1476

title

Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response

P478

volume

123

Reverse relations

cites work (P2860)

Q30361699	Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report.
Q41420993	Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?
Q90672492	Antithrombotic Agents and Cancer
Q60907235	Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis
Q49217433	C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.
Q64055605	Clinical development of targeted and immune based anti-cancer therapies
Q47094540	Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models
Q34119737	Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice
Q39089774	Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process
Q39417846	Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Q42314537	Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice
Q30361046	Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
Q90480230	Endothelial barrier protective properties of low molecular weight heparin: A novel potential tool in the prevention of cancer metastasis?
Q89943975	Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: A Focus on P-Selectin
Q28657828	Heparan sulfate signaling in cancer
Q50075235	In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema
Q38696359	Integrin β3/Akt signaling contributes to platelet-induced hemangioendothelioma growth.
Q33413168	Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation
Q38214959	Mechanistic explanation for platelet contribution to cancer metastasis
Q36246228	Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.
Q26825427	Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
Q49234113	Platelet-inspired medicine for tumor therapy
Q39294808	Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting
Q38584175	Platelets in cancer metastasis: To help the "villain" to do evil
Q58702065	Role of COX-2/PGE2 Mediated Inflammation in Oral Squamous Cell Carcinoma
Q57280930	Role of platelets and platelet receptors in cancer metastasis
Q33808326	Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth
Q38284002	Systems biology of platelet-vessel wall interactions
Q51155744	Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.
Q39454244	Targeting Platelets for the Treatment of Cancer.
Q55318767	The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.
Q52719266	The Platelet Lifeline to Cancer: Challenges and Opportunities.
Q59335689	The Platelet Response to Tissue Injury
Q64246098	The Role of Platelets in the Tumor-Microenvironment and the Drug Resistance of Cancer Cells
Q38842991	The angiogenic responses induced by release of angiogenic proteins from tumor cell-activated platelets are regulated by distinct molecular pathways
Q41656424	The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink.
Q38212058	The functional role of platelets in the regulation of angiogenesis
Q48218215	The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
Q57301724	The prognostic impact of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patients with advanced colorectal cancer treated with first-line chemotherapy
Q37088087	The prothrombotic activity of cancer cells in the circulation
Q97538185	Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation
Q57810885	Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
Q40501806	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
Q40671371	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans